A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
Market
0.0%
Details
- Resolved Date
- 12/26/25
- Study Completion
- 3/26/26
- Company
- Janssen Research & Development, LLC
- Ticker
- JNJ
- Type
- Trial Status
- Active Not Recruiting
- Trial Size
- 256
- Volume
- $0
- NCT
- NCT06881251
- Drug Description
- The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
Resolution Evidence
- Outcome
- NO
- Status
- Resolved
- Settlement Date
- 4/3/26 UTC
- Executive Summary
Exact-trial evidence is negative. J&J’s public statement on DUPLEX-AD says the planned interim analysis triggered early termination because the study did not meet the efficacy bar for advancing in atopic dermatitis. ClinicalTrials.gov identifies DUPLEX-AD as NCT06881251.
Sources
Sponsorjnj.com12/26/25
Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study
J&J said the Phase 2b DUPLEX-AD interim analysis met criteria for early termination because it did not meet the efficacy bar set for advancing its atopic dermatitis program.
View source
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06881251 | A Study of JNJ-95475939 in Moderate to Severe Atopic Dermatitis
ClinicalTrials.gov identifies NCT06881251 as the DUPLEX-AD study evaluating JNJ-95475939 in moderate to severe atopic dermatitis.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
